Corinne Johnson
Stock Analyst at Goldman Sachs
(3.22)
# 1,059
Out of 5,148 analysts
15
Total ratings
50%
Success rate
20.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Neutral | $37 → $39 | $30.09 | +29.61% | 1 | Jan 15, 2026 | |
| IMVT Immunovant | Maintains: Neutral | $18 → $28 | $27.73 | +0.97% | 2 | Dec 15, 2025 | |
| MBX MBX Biosciences | Initiates: Sell | $18 | $32.55 | -44.70% | 1 | Dec 4, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $15.17 | +31.84% | 2 | Sep 16, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $20 → $24 | $21.71 | +10.55% | 2 | Sep 5, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $22.97 | +43.67% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $132.25 | +37.62% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $58.80 | -14.97% | 3 | May 14, 2024 |
TG Therapeutics
Jan 15, 2026
Maintains: Neutral
Price Target: $37 → $39
Current: $30.09
Upside: +29.61%
Immunovant
Dec 15, 2025
Maintains: Neutral
Price Target: $18 → $28
Current: $27.73
Upside: +0.97%
MBX Biosciences
Dec 4, 2025
Initiates: Sell
Price Target: $18
Current: $32.55
Upside: -44.70%
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $15.17
Upside: +31.84%
Syndax Pharmaceuticals
Sep 5, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $21.71
Upside: +10.55%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $22.97
Upside: +43.67%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $132.25
Upside: +37.62%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $58.80
Upside: -14.97%